Quote:

---

As a surgeon, Bertagnolli specializes in gastrointestinal tumors. In her lab, she studies a gene named APC (adenomatous polyposis coli), how its mutation or loss initiates tumor transformation and whether drugs that work on this pathway can treat colorectal cancer.

---

Very interesting. APC is protective against cancer mainly through blocking activation of beta-catenin. Our old friend CCL5 (RANTES) and CCL2 (another CCR5 ligand) upregulates beta-catenin activition. Leronlimab of course would downregulate that activation. Almost certainly Dr. Bertagnolli is aware of this.

Beta-catenin is also implicated in quite a number of other cancers.